The IRDD Stream is designed for senior industry experts that will showcase new trends in aerosol science and the future directions of inhalation drug delivery research. Further discussion focusses on the regulatory pathways for inhaled therapies and challenges of bringing respiratory products to market. The agenda also features key case studies on the latest trends in inhalation devices, from inhaled ins. to gene therapy.

A recent report from the Pharmaceutical Research and Manufacturers of America (PhRMA) found America’s biopharmaceutical companies are developing about 130 new medicines for the millions of patients affected by respiratory diseases: chronic obstructive pulmonary disease (COPD), cystic fibrosis, pneumonia, and asthma. These medicines represent critical advancements in respiratory care and improving quality of life. In addition to the drugs, devices delivering those products are being designed to improve the quality of life for an aging population, children, and those who tend not to comply to dosing regimens because they don’t know how to use the device. The global respiratory care devices market is expected to exceed more than $24 billion by 2022,2 and could exceed $33 billion by 2023.

This stream will focus on the challenges of bringing respiratory products to market and innovative aerosol science, including modelling and toxicology. Presentations will also feature key case studies on the latest trends in inhalation devices, from inhaled ins. to gene therapy to overcome lung and pulmonary conditions, such as COPD, asthma and cystic fibrosis. The event highlights some of the innovators and innovations in the respiratory sector, addresses the importance of end users in the device development process, and presents recent advancements in improving patient adherence.

Key Practical Points

  • Novel technologies for pulmonary & nasal delivery
  • Modern respiratory medicines
  • Innovative development of inhalation devices
  • Digital health combination products
  • Analytical tools for inhaled medicines
  • Challenges of bringing inhalation and respiratory drug delivery products to market
  • Regulatory updates in the global respiratory market
  • The challenges of developing inhalation devices
  • Alternative therapeutic fields
  • Innovation in nebulised therapy
  • Triple inhaler therapy in COPD
  • Inhaled drugs through functional respiratory imaging (FRI) and artificial intelligence (AI)
  • Dry-powder inhalers (DPIs) and Metered-dose inhalers (MDIs)
  • New analytical insights into dry powder formulations for inhalation
  • Routes to controlling aerosol response
  • Characterizing aerosol dynamics
  • Model validation
  • Future directions in inhalation and respiratory drug delivery research
  • Regulatory pathways for inhaled therapies
  • Strategies for Managing the Impact of Brexit
  • Challenges of developing a generic inhaled product
  • Explore opportunities with smart and digital inhalers

Who should attend?

Members of board, C-level, Senior Vice Presidents, Vice Presidents, Directors and Heads of departments from pharmaceutical/biotechnology industry / industries involved in:

  • Respiratory Drug Development
  • Generics & Respiratory
  • Inhalation Drug Delivery Technologies
  • Device Development and Engineering
  • Respiratory Pharmacology
  • Medical Devices & Injectors
  • Inhalation Device Development
  • Inhaled Formulation Science
  • Inhalation Product Development
  • Respiratory Regulations
  • Generics & Respiratory
  • Inhalation Process Development
  • Respiratory Medicine
  • Inhalation Drug Delivery
  • E-Health
  • Inhaled Dosage Forms
  • Outsourcing
  • Process Development
  • Respiratory Pharmacology
  • Device Engineering
  • Drug Delivery Innovation
  • Inhalation Devices
  • Metered Dose Inhaler Development
  • Medical Marketing
  • Respiratory R&D
  • Particle Characterisation
  • Business Development
  • New Delivery Technologies
  • Connective Health
  • Respiratory Regulations
  • Pulmonary Disease
  • Inhalation
  • Scientific Research

Keynote Speakers

Slide FEATURED Arkadiusz
Arkadiusz K. Kuczaj earned his PhD (2006) in the field of Applied Mathematics from the University of Twente, the Netherlands. As Manager of Aerosol Research and Dosimetry, he is currently leading aerosol delivery and characterization, in vitro exposure, and in vivo inhalation research in the Biomedical Research Department (BMRD) at Philip Morris International MANAGER AEROSOL RESEARCH AND DOSIMETRY AT PHILIP MORRIS INTERNATIONAL
Slide FEATURED Beatriz
Beatriz Noriega Fernandes holds a MSc Degree in Biological Engineering by Instituto Superior Técnico, University of Lisbon, 2015. She joined Hovione in the same year as an Industrial PhD Candidate in collaboration with Faculty of Pharmacy, University of Lisbon, specializing in dissolution methodologies and in vivo/in vitro correlations for dry powder inhaler formulations. SCIENTIST, FORMULATION GROUP - DRUG PRODUCT DEVELOPMENT AT HOVIONE
Slide FEATURED Marco
Marco Laackmann has an Engineering degree in Chemical Engineering applied Biotechnology from University of Applied Science Emden in Germany and a MBA from Bradford School of Management in UK. DIRECTOR INHALATION TECHNOLOGY AT HARRO HÖFLIGER
Slide FEATURED Francesca
Dr. Francesca Buttini is Associate Professor at the Food and Drug Department, University of Parma (IT) where she is leading the unit dedicated to design of pharmaceutical products for inhalation. ASSOCIATE PROFESSOR AT UNIVERSITY OF PARMA, ITALY
View all speakers

Exhibitors & Sponsors

Booth #E1

Philip Morris International

Philip Morris is the leading international Tobacco Company with the objectives to be environmentally and socially responsible. Their mission is to operate with integrity, and focus on responsibly delivering long-term, sustainable growth.

Philip Morris supports effective evidence-based regulation of tobacco products and invests in developing and assessing products with the potential to reduce the risk of tobacco-related disease. Over 82,000 people from all five continents, speaking more than 80 languages, make up the success of their company.

Booth #E6


MUNIT is a new and innovative consultancy company, operating in the field of MICRONIZATION of Active Pharmaceutical Ingredients (APIs), High Potent APIs, Cytotoxic and Cytostatic compounds, Inhalation products, Steroids, R&D compounds and Generics. In MUNIT we have combined the technical and commercial expertise of its affiliates Jetpharma SA (Switzerland) and Microchem Srl (Italy) making the best out of 40 years of leadership.

Booth #E15

Harro Höfliger

Booth #E7



Gallery from previous edition